{"id":"ingenol-mebutate-0-015","safety":{"commonSideEffects":[{"rate":"80–90","effect":"Application site erythema"},{"rate":"50–70","effect":"Application site pain"},{"rate":"40–60","effect":"Application site edema"},{"rate":"20–40","effect":"Application site pruritus"},{"rate":"30–50","effect":"Crusting/scabbing"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ingenol mebutate activates protein kinase C, leading to direct cytotoxic effects on keratinocytes and induction of an inflammatory response that recruits immune cells to eliminate dysplastic cells. The drug causes rapid cell death in actinic keratosis lesions while simultaneously triggering local immune activation, resulting in clearance of both treated and untreated lesions in the surrounding area.","oneSentence":"Ingenol mebutate is a protein kinase C (PKC) activator that induces rapid necrosis of actinic keratosis cells and promotes immune-mediated clearance of damaged skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:58.752Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis (field treatment on face or scalp)"}]},"trialDetails":[{"nctId":"NCT01541553","phase":"PHASE3","title":"A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-03","conditions":"Actinic Keratosis","enrollment":367},{"nctId":"NCT01600014","phase":"PHASE3","title":"Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Actinic Keratosis","enrollment":463},{"nctId":"NCT01926496","phase":"PHASE4","title":"Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09-11","conditions":"Actinic Keratosis (AK)","enrollment":485},{"nctId":"NCT01787383","phase":"PHASE3","title":"A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-02","conditions":"Actinic Keratosis","enrollment":200},{"nctId":"NCT02406014","phase":"PHASE4","title":"Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Actinic Keratosis (AK)","enrollment":502},{"nctId":"NCT03336372","phase":"EARLY_PHASE1","title":"Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients","status":"WITHDRAWN","sponsor":"Center for Clinical Studies, Texas","startDate":"2017-12-20","conditions":"Molluscum Contagiosum","enrollment":""},{"nctId":"NCT02866695","phase":"PHASE4","title":"Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-10-06","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT03200912","phase":"PHASE3","title":"An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-08-19","conditions":"ACTINIC KERATOSIS","enrollment":507},{"nctId":"NCT02421471","phase":"","title":"PMS to Evaluate the Safety and Efficacy of Picato® Gel","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-09","conditions":"Actinic Keratosis","enrollment":1324},{"nctId":"NCT02446223","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%","status":"COMPLETED","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2015-01","conditions":"Actinic Keratosis","enrollment":21},{"nctId":"NCT02354391","phase":"PHASE2","title":"Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis","status":"UNKNOWN","sponsor":"Pacific Dermaesthetics","startDate":"2015-01","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT02594436","phase":"","title":"The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-12-01","conditions":"Actinic Keratosis","enrollment":440},{"nctId":"NCT03569345","phase":"PHASE1, PHASE2","title":"Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate","status":"COMPLETED","sponsor":"Merete Haedersdal","startDate":"2017-11-17","conditions":"Carcinoma, Basal Cell","enrollment":20},{"nctId":"NCT03508856","phase":"NA","title":"Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin","status":"COMPLETED","sponsor":"Skin Laser & Surgery Specialists","startDate":"2015-11-09","conditions":"Actinic Keratosis, Photo-aged Skin","enrollment":23},{"nctId":"NCT02716714","phase":"PHASE4","title":"Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis","status":"COMPLETED","sponsor":"Korea University","startDate":"2015-04","conditions":"Actinic Keratosis","enrollment":77},{"nctId":"NCT02281682","phase":"PHASE4","title":"IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2014-11","conditions":"Keratosis, Actinic","enrollment":624},{"nctId":"NCT02411851","phase":"PHASE1","title":"Treatment of Actinic Keratoses (AK) on the Face","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2015-03","conditions":"Actinic Keratoses","enrollment":20},{"nctId":"NCT01302925","phase":"PHASE1","title":"PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy Subjects","status":"COMPLETED","sponsor":"Peplin","startDate":"2011-02","conditions":"Healthy, Actinic Keratosis","enrollment":100},{"nctId":"NCT00700063","phase":"PHASE2","title":"A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","status":"COMPLETED","sponsor":"Peplin","startDate":"2008-06","conditions":"Actinic Keratosis","enrollment":265},{"nctId":"NCT00916006","phase":"PHASE3","title":"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-06","conditions":"Actinic Keratosis","enrollment":269},{"nctId":"NCT00915551","phase":"PHASE3","title":"A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","status":"COMPLETED","sponsor":"Peplin","startDate":"2009-06","conditions":"Actinic Keratosis","enrollment":278},{"nctId":"NCT02242747","phase":"NA","title":"Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2014-05","conditions":"Actinic Keratosis","enrollment":100},{"nctId":"NCT01836367","phase":"PHASE1","title":"Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2013-03","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT01214577","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin","status":"COMPLETED","sponsor":"Peplin","startDate":"2010-10","conditions":"Photo-damage","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ingenol mebutate 0.015% qdaily x 3 days for two cycles","Picato® gel","Picato"],"phase":"marketed","status":"active","brandName":"ingenol mebutate 0.015%","genericName":"ingenol mebutate 0.015%","companyName":"Icahn School of Medicine at Mount Sinai","companyId":"icahn-school-of-medicine-at-mount-sinai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ingenol mebutate is a protein kinase C (PKC) activator that induces rapid necrosis of actinic keratosis cells and promotes immune-mediated clearance of damaged skin. Used for Actinic keratosis (field treatment on face or scalp).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}